{
  "symbol": "REGN",
  "year": 2023,
  "period": "Y2023",
  "curated_text": "Symbol: REGN. Year: 2023. Period: Y2023. ReportType: K10. Section: Competition and Market Position. This section discusses competitors, market dynamics, and regulatory landscape.  Competitors mentioned: Marketed Products, New Indications, Novartis AG, Genentech/Roche, DME, RVO, Samsung Bioepis Co., Ltd., Biogen Inc., AMD, Bausch + Lomb, STADA Arzneimittel AG, CNV EU Cimerli, Lucentis), Formycon AG, Bioeq AG, Coherus BioSciences, Inc., Teva Ltd., Genentech/Roche Wet, Genentech/Roche Wet AMD, RVO Worldwide Beovu \u00ae, DME Worldwide Ozurdex \u00ae, Allergan/AbbVie Inc. DME, EU, Product Competitor Indication Territory, Alimera Sciences, Inc., EU Conbercept Chengdu Kanghong Pharmaceutical Group Co., China Dupixent, United States, Eli Lilly and Company/Incyte Corporation Moderate, LEO Pharma Inc., Worldwide Corectim \u00ae, Japan Tobacco Inc./Torii Pharmaceutical Co.,, Maruho Co., Pharmaceutical Co., Roche/Novartis Asthma, nasal polyps, GSK, AstraZeneca/Amgen Asthma Worldwide, pembrolizumab) Merck & Co., Worldwide Opdivo \u00ae, Bristol-Myers Squibb, EU Praluent Repatha \u00ae, HoFH Worldwide, Novartis Primary, Genentech/Roche/Chugai Pharmaceutical Co., Ltd. Rheumatoid, Bristol-Myers Squibb Rheumatoid, Pfizer Rheumatoid, Eli Lilly/Incyte Rheumatoid, Gilead Sciences, NV Rheumatoid, VelocImmune, Consolidated Financial Statements, VelociSuite, Product Molecule Territory Patent, JP 4,723,140 Composition, JP 5,273,746 Methods of Treatment June 24, JP 5,216,002 Formulation, 24 Table of Contents Product, JP 5,291,802 Composition, JP, JP 6,306,588 Methods of Treatment, JP 6,353,838 Methods of Treatment September 4, 2033, JP 6,861,630 Methods of Treatment, JP 6,425,730 Composition, JP 6,999,577 Methods of Treatment, JP 7,054,680 Methods of Treatment, JP 5,307,708 Composition, JP 5,805,660 Formulation, JP 7,025,477 Methods of Treatment, JP 7,166,925 Methods of Treatment March 7, 2037, Trademark Office, the U.S. Patent and Trademark Office, Dupixent, FDA, the Federal Food, Drug and Cosmetic Act. Context excerpt: Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and other factors. Marketed Products The table below provides an overview of the current competitive landscape for the key products marketed by us and/or our collaborators in such products' currently approved indications. The table below is provided for illustrative purposes only and is not exhaustive. For additional information regarding the substantial competition these marketed products face, including potential future competition from product candidates in clinical development, see also Part I, Item",
  "competition_summary": [
    {
      "competitor": "Marketed Products",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "New Indications",
      "mentions": 2,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Novartis AG",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Genentech/Roche",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "DME",
      "mentions": 7,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "RVO",
      "mentions": 4,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Samsung Bioepis Co., Ltd.",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Biogen Inc.",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "AMD",
      "mentions": 5,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Bausch + Lomb",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "STADA Arzneimittel AG",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "CNV EU Cimerli",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Lucentis)",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Formycon AG",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Bioeq AG",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Coherus BioSciences, Inc.",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Teva Ltd.",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Genentech/Roche Wet",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Genentech/Roche Wet AMD",
      "mentions": 2,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "RVO Worldwide Beovu \u00ae",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "DME Worldwide Ozurdex \u00ae",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Allergan/AbbVie Inc. DME",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "EU",
      "mentions": 8,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Product Competitor Indication Territory",
      "mentions": 2,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Alimera Sciences, Inc.",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "EU Conbercept Chengdu Kanghong Pharmaceutical Group Co.",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "China Dupixent",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "United States",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Eli Lilly and Company/Incyte Corporation Moderate",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "LEO Pharma Inc.",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Worldwide Corectim \u00ae",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Japan Tobacco Inc./Torii Pharmaceutical Co.,",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Maruho Co.",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Pharmaceutical Co.",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Roche/Novartis Asthma",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "nasal polyps",
      "mentions": 2,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "GSK",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "AstraZeneca/Amgen Asthma Worldwide",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "pembrolizumab) Merck & Co.",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Worldwide Opdivo \u00ae",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Bristol-Myers Squibb",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "EU Praluent Repatha \u00ae",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "HoFH Worldwide",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Novartis Primary",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Genentech/Roche/Chugai Pharmaceutical Co., Ltd. Rheumatoid",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Bristol-Myers Squibb Rheumatoid",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Pfizer Rheumatoid",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Eli Lilly/Incyte Rheumatoid",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Gilead Sciences",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "NV Rheumatoid",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "VelocImmune",
      "mentions": 2,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Consolidated Financial Statements",
      "mentions": 2,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "VelociSuite",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Product Molecule Territory Patent",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "JP 4,723,140 Composition",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "JP 5,273,746 Methods of Treatment June 24",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "JP 5,216,002 Formulation",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "24 Table of Contents Product",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "JP 5,291,802 Composition",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "JP",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "JP 6,306,588 Methods of Treatment",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "JP 6,353,838 Methods of Treatment September 4, 2033",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "JP 6,861,630 Methods of Treatment",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "JP 6,425,730 Composition",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "JP 6,999,577 Methods of Treatment",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "JP 7,054,680 Methods of Treatment",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "JP 5,307,708 Composition",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "JP 5,805,660 Formulation",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "JP 7,025,477 Methods of Treatment",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "JP 7,166,925 Methods of Treatment March 7, 2037",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Trademark Office",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "the U.S. Patent and Trademark Office",
      "mentions": 3,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "Dupixent",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "FDA",
      "mentions": 2,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    },
    {
      "competitor": "the Federal Food, Drug and Cosmetic Act",
      "mentions": 1,
      "context": "Competition We face substantial competition from pharmaceutical, biotechnology, and chemical companies. Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market. Competition among products approved for sale is based on efficacy, safety, reliability, availability, price, patent and other intellectual property position, and othe"
    }
  ]
}